abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile

This publication has 11 references indexed in Scilit:

• Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
  Journal of the American College of Cardiology, 2001
• Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial
  The Lancet, 2000
• Abciximab provides cost-effective survival advantage in high-volume interventional practice
  American Heart Journal, 2000
• Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors
  New England Journal of Medicine, 1999
• Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty
  Circulation, 1997
• Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
  New England Journal of Medicine, 1997
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
  The Lancet, 1997
• Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary palmaz-schatz stenting
  Journal of the American College of Cardiology, 1996
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA.
  Circulation, 1993